ArticleDermatology and therapy2025
Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program.
Article in Dermatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Real-world Tildrakizumab Effectiveness and Drug Survival: A Cohort Study in the PPD CorEvitas Psoriasis Registry.Dermatology and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTildrakizumab is an anti-interleukin-23 p19 monoclonal antibody approved in several countries to treat adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Limited data are available on tildrakizumab treatment patterns in clinical practice. The Canadian tildrakizumab patient support program (PSP), which provides personalized reimbursement, financial aid, and injection training support for disease management, was used in this study to evaluate real-world persistence and adherence to tildrakizumab.
methodsThis retrospective, observational study used data collected in the Canadian tildrakizumab PSP database between August 4, 2021, and August 1, 2023. Adult (≥18 years) patients with moderate-to-severe plaque psoriasis who enrolled in the PSP and received ≥6 months of treatment with tildrakizumab before August 1, 2023, were included. Data up to Week 52 following treatment initiation were analyzed. Persistence was defined as the number of days until treatment discontinuation. Adherence was measured as the proportion of days covered (PDC) from treatment initiation to treatment discontinuation or study cutoff, with PDC ≥80% indicating high adherence.
resultsThe study included 813 patients with a mean ± standard deviation (SD) age of 49.6 ± 15.9 years; 55.0% (447/813) were male, and 92.7% (754/813) were biologic-naïve when initiating tildrakizumab. Patients received tildrakizumab treatment for a mean ± SD of 329.6 ± 55.0 days. After 1 year, 88.0% of patients were persistent on treatment. Adherence was also high, with mean ± SD PDC being 97.5% ± 8.9% and 93.5% of patients having PDC ≥80%. Eighty-five patients discontinued treatment, primarily because of switching to other therapies. Common adverse outcomes included treatment misuse (18.9%), disease flare (8.2%), and treatment discontinuation (7.4%).
conclusionPersistence and adherence to tildrakizumab were high through 52 weeks of treatment among patients with moderate-to-severe plaque psoriasis enrolled in the Canadian PSP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.